- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01371214
Preventing Loss of Independence Through Exercise (PLIÉ) - Pilot (PLIÉ-pilot)
June 2, 2015 updated by: Deborah Barnes, University of California, San Francisco
Maintaining Independence in Alzheimer's Disease
The primary goal of this study is to perform a 36-week pilot study with a cross-over design to study the safety and efficacy of a novel integrative exercise program called PLIÉ (Preventing Loss of Independence through Exercise).
PLIÉ integrates elements of Eastern and Western exercise traditions and is specifically designed to target the muscles and movements needed to help individuals with mild-to-moderate dementia maintain physical function and independence.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94118
- Irene Swindells Center for Adult Day Services, Institute on Aging
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria - Primary Participant:
- Current participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
- Recommended by Swindells staff
- mild-to-moderate dementia
- caregiver consent
Inclusion Criteria - Caregiver:
- Provide care to primary participant in the Irene Swindells Center for Adult Day Services in San Francisco, CA
- can provide information about the primary participant's physical functioning, behaviors, falls, quality of life and own level of stress.
Exclusion Criteria - Primary Participant:
- major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
- life expectancy < 1 year (e.g., metastatic cancer)
- inability to assent to study procedures
Exclusion Criteria - Caregiver:
- Any major neurologic disease (e.g., dementia, stroke, Parkinson's disease, ALS)
- major current psychiatric illness (e.g., schizophrenia, bipolar disorder)
- life expectancy < 1 year (e.g., metastatic cancer)
- evidence of cognitive impairment
- inability to consent to study procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Group 1
PLIÉ exercise program 30-45 minutes, 2-3 days/week for 18 weeks followed by 18 weeks of usual care (20-minutes of chair-based exercises 2-5 days/week).
|
Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
|
|
Active Comparator: Group 2
Usual care (20 minutes of chair-based exercises 2-5 days/week) for 18 weeks followed by the PLIÉ exercise program 30-45 minutes/day, 2-3 days/week for 18 weeks.
|
Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in physical function (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Participant's physical function will be assessed with the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale (Galasko 1997).
The ADCS-ADL is a 78-point scale that assesses functional ability in 23 daily activities based on informant report.
It is the standard measure for assessment of functional status in AD treatment trials.
|
Baseline, 18 weeks, 36 weeks
|
|
Change in quality of life (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Quality of life will be assessed with the Quality of Life Scale in Alzheimer's Disease (QOL-AD), which is a brief, 13-item measure that obtains input from both the individual and the caregiver (Logsdon 1999).
Scores may range from 13-52 points.
|
Baseline, 18 weeks, 36 weeks
|
|
Change in functional health and well-being (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Functional health and well-being will be assessed with the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989).
The SF-36v2 is typically administered directly to participants.
However, we also will ask caregivers to answer questions on behalf of participants and will compare their answers to assess congruence.
Data collected will help to determine if this measure is suitable for a larger trial.
|
Baseline, 18 weeks, 36 weeks
|
|
Change in number of falls (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Participant's falls will be assessed based on caregiver report.
|
Baseline, 18 weeks, 36 weeks
|
|
Change in fall-related self-efficacy (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Fall-related self-efficacy will be assessed with the Falls Efficacy Scale (FES), which is a 10-item scale that has been validated in individuals with cognitive impairment (Hauer 2010).
|
Baseline, 18 weeks, 36 weeks
|
|
Change in physical performance (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Physical performance will be assessed with the Short Physical Performance Battery (SPPB), which was developed by the National Institute on Aging to provide an objective tool for evaluating lower extremity functioning in older adults.
The test includes repeated chair stands, tandem balance testing and 8' walking speed (Guralnik 1994).
|
Baseline, 18 weeks, 36 weeks
|
|
Change in cognitive function (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Cognitive function will be assessed with the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog) (Rosen 1984), which is the most commonly used primary outcome measure in AD treatment trials.
It is an 80-point scale that includes direct assessment of learning (word list), naming (objects), following commands, constructional Praxis (figure copying), ideational Praxis (mailing a letter), orientation (person, time, place), recognition memory and remembering test instructions.
|
Baseline, 18 weeks, 36 weeks
|
|
Compliance (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Participant compliance will be determined based on % of exercise classes attended from baseline to 18 weeks and from 18-36 weeks.
|
Baseline, 18 weeks, 36 weeks
|
|
Adverse events (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Number of adverse events from baseline to 18 weeks and from 18 weeks to 36 weeks will be monitored through biweekly telephone calls with caregivers.
|
Baseline, 18 weeks, 36 weeks
|
|
Change in dementia-related behaviors (participant)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Participant's dementia-related behaviors will be assessed with the Neuropsychiatric Inventory (NPI), which is a 144-point informant-based questionnaire that assesses 12 behavioral domains common in dementia including frequency, severity and impact on caregiver distress (Cummings 1997).
|
Baseline, 18 weeks, 36 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in functional health and well-being (caregiver)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Caregivers will be asked about the functional health and well-being of themselves as well as participants using the SF-36v2, which assesses function in eight domains and provides physical and mental component summary scores that may range from 0 to 70 (Stewart 1989).
|
Baseline, 18 weeks, 36 weeks
|
|
Change in burden (caregiver)
Time Frame: Baseline, 18 weeks, 36 weeks
|
Caregiver burden will be assessed with the Caregiver Burden Inventory (CBI), which is a 96-point scale that includes 24 items and 5 domains (Novak 1989).
|
Baseline, 18 weeks, 36 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Margaret Chesney, PhD, University of California, San Francisco
- Principal Investigator: Deborah E Barnes, PhD, MPH, University of California, San Francisco
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wu E, Barnes DE, Ackerman SL, Lee J, Chesney M, Mehling WE. Preventing Loss of Independence through Exercise (PLIE): qualitative analysis of a clinical trial in older adults with dementia. Aging Ment Health. 2015;19(4):353-62. doi: 10.1080/13607863.2014.935290. Epub 2014 Jul 14.
- Barnes DE, Mehling W, Wu E, Beristianos M, Yaffe K, Skultety K, Chesney MA. Preventing loss of independence through exercise (PLIE): a pilot clinical trial in older adults with dementia. PLoS One. 2015 Feb 11;10(2):e0113367. doi: 10.1371/journal.pone.0113367. eCollection 2015.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2011
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
September 1, 2012
Study Registration Dates
First Submitted
June 7, 2011
First Submitted That Met QC Criteria
June 8, 2011
First Posted (Estimate)
June 10, 2011
Study Record Updates
Last Update Posted (Estimate)
June 3, 2015
Last Update Submitted That Met QC Criteria
June 2, 2015
Last Verified
June 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10-04080-023906
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
Benjamin Rose Institute on AgingNational Institute on Aging (NIA)RecruitingMild Dementia | Moderate DementiaUnited States
-
Yaolin PeiNational Institutes of Health (NIH)RecruitingEnd of Life Decision Making | Dementia Caregivers | Advanced DementiaUnited States
-
Benuvia Therapeutics Inc.MandaraNot yet recruiting
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityCompletedDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeActive, not recruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityCompletedDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
NYU Langone HealthRecruiting
-
The University of Hong KongNot yet recruiting
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
Clinical Trials on PLIÉ (Preventing Loss of Independence through Exercise)
-
University of California, San FranciscoUnited States Department of DefenseCompletedMild Cognitive ImpairmentUnited States
-
VA Office of Research and DevelopmentEnrolling by invitationCognitive Dysfunction | DementiaUnited States
-
VA Office of Research and DevelopmentLifeLong Marin Adult Day Health Center; Institute on Aging, San Francisco, CA; Catholic Charities, Santa Rosa,... and other collaboratorsCompletedDementia | Alzheimer's DiseaseUnited States
-
University of California, San FranciscoUniversity of California, Los Angeles; United States Department of Defense; San... and other collaboratorsCompletedMild Cognitive Impairment | Subjective Memory DeclineUnited States
-
California Polytechnic State University-San Luis...CompletedA Pilot Study Using Weightloss and Exercise to Prevent Recurring Gestational Diabetes in Obese WomenGestational DiabetesUnited States
-
University of Beira InteriorCompletedThis Study Highlights Differences in Baropodometry Between GendersPortugal
-
St. Luke's-Roosevelt Hospital CenterCompletedHIV Infections | Obesity | Insulin ResistanceUnited States
-
CureVacCompletedCovid19 | SARS-CoV-2Belgium, Spain, Germany, Argentina, Colombia, Dominican Republic, Mexico, Netherlands, Panama, Peru
-
University of Colorado, DenverCompleted
-
Memorial Sloan Kettering Cancer CenterJohns Hopkins University; St. Jude Children's Research HospitalCompletedAdult Survivors of Childhood LeukemiaUnited States